Lucy Parkinson is CEO of Boston Innovation Capital and VP of Investor Research, leading LSN’s investor outreach and analysis team. In over five years as an employee of both Life Science Nation and Boston Innovation Capital, she has analyzed global investors and channel partners in depth and determined which have vetted mandates and are a fit for her clients. She leads a team of global investor research analysts that curate the LSN Investor Platform, which tracks 10 categories of early-stage life science investors across the silos of drugs, devices, diagnostics and digital health. Lucy also runs the programming of LSN’s Redefining Early Stage Investments (RESI) Conference Series, which hosts about 2000 investors annually. She was a contributing writer for The Life Science Executive’s Fundraising Manifesto and to two articles published in Nature Bioentrepreneur, as well as being a frequent contributor to LSN’s Next Phase weekly newsletter. Prior to joining LSN, Lucy spent several years working at CPA firms, gaining experience working with small corporations, partnerships and nonprofit organizations. Lucy graduated from the University of Leeds with a degree in the History and Philosophy of Science. She is a FINRA-registered securities representative and principal, holding Series 7,24, and 63 registrations.